Sio Capital Management, LLC reported 50 positions worth $568.13M for the quarter ended Jun 30, 2026, down 15.4% on the prior quarter. It opened 13 new positions, added to 10, trimmed 20 and exited 27. Its largest holding is Anteris Technologies Global Corp. at 9.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ALLO Allogene Therapeutics, Inc. | +13.32M | – | $27.71M | 4.88% |
| GMED Globus Medical Inc | +301.8K | – | $23.85M | 4.2% |
| COR Cencora, Inc. | +72.7K | +72.0% | $20.57M | 8.65% |
| IDYA IDEAYA Biosciences, Inc. | +480.4K | – | $17.90M | 3.15% |
| CI Cigna Group | +57.8K | – | $15.92M | 2.8% |
| VTRS Viatris Inc | +954.3K | – | $15.15M | 2.67% |
| REGN Regeneron Pharmaceuticals, Inc. | +18.0K | – | $11.22M | 1.98% |
| BMY Bristol Myers Squibb Co | +193.5K | – | $11.15M | 1.96% |
| MDT Medtronic plc | +142.5K | – | $11.15M | 1.96% |
| HELP Helus Pharma Inc. | +1.30M | – | $8.59M | 1.51% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ICLR Icon Plc | -218.2K | -71.2% | $37.90M | 2.7% |
| DNTH Dianthus Therapeutics, Inc. | -310.8K | -84.0% | $30.30M | 1.02% |
| CORT Corcept Therapeutics Inc | -674.8K | -100.0% | $27.20M | Exited |
| LIVN LivaNova PLC | -421.6K | -100.0% | $26.80M | Exited |
| EMBC Embecta Corp. | -1.85M | -100.0% | $16.33M | Exited |
| ABVX Abivax S.A. | -135.8K | -100.0% | $15.12M | Exited |
| WAY Waystar Holding Corp. | -716.4K | -43.6% | $14.71M | 3.35% |
| ANIP Ani Pharmaceuticals Inc | -168.2K | -63.4% | $13.93M | 1.42% |
| HAE Haemonetics Corp | -220.7K | -100.0% | $12.44M | Exited |
| TFX Teleflex Inc | -94.8K | -100.0% | $11.34M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ALLO Allogene Therapeutics, Inc. | +13.32M | $27.71M | 4.88% |
| GMED Globus Medical Inc | +301.8K | $23.85M | 4.2% |
| IDYA IDEAYA Biosciences, Inc. | +480.4K | $17.90M | 3.15% |
| CI Cigna Group | +57.8K | $15.92M | 2.8% |
| VTRS Viatris Inc | +954.3K | $15.15M | 2.67% |
| REGN Regeneron Pharmaceuticals, Inc. | +18.0K | $11.22M | 1.98% |
| BMY Bristol Myers Squibb Co | +193.5K | $11.15M | 1.96% |
| MDT Medtronic plc | +142.5K | $11.15M | 1.96% |
| HELP Helus Pharma Inc. | +1.30M | $8.59M | 1.51% |
| TNGX Tango Therapeutics, Inc. | +208.5K | $6.52M | 1.15% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| CORT Corcept Therapeutics Inc | -674.8K | $27.20M | 4.05% |
| LIVN LivaNova PLC | -421.6K | $26.80M | 3.99% |
| EMBC Embecta Corp. | -1.85M | $16.33M | 2.43% |
| ABVX Abivax S.A. | -135.8K | $15.12M | 2.25% |
| HAE Haemonetics Corp | -220.7K | $12.44M | 1.85% |
| TFX Teleflex Inc | -94.8K | $11.34M | 1.69% |
| BMRN Biomarin Pharmaceutical Inc | -194.2K | $10.97M | 1.63% |
| GPCR Structure Therapeutics Inc. | -209.1K | $10.08M | 1.5% |
| BHVN Biohaven Ltd. | -1.16M | $9.85M | 1.47% |
| MNPR Monopar Therapeutics | -173.5K | $9.51M | 1.41% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVR Anteris Technologies Global Corp. | Healthcare | 5.55M | $54.63M | 9.62% | +163.0K | +3.0% | Added | 5.69% |
| 2 | COR Cencora, Inc. | Healthcare | 173.6K | $49.12M | 8.65% | +72.7K | +72.0% | Added | 0.09% |
| 3 | MMS Maximus, Inc. | Industrials | 715.3K | $38.45M | 6.77% | -53.6K | -7.0% | Reduced | 1.35% |
| 4 | ALLO Allogene Therapeutics, Inc. | Healthcare | 13.32M | $27.71M | 4.88% | +13.32M | – | New | 3.86% |
| 5 | GMED Globus Medical Inc | Healthcare | 301.8K | $23.85M | 4.2% | +301.8K | – | New | 0.27% |
| 6 | GSK GSK plc | Healthcare | 436.7K | $22.89M | 4.03% | +50.8K | +13.2% | Added | 0.02% |
| 7 | TYRA Tyra Biosciences, Inc. | Healthcare | 695.3K | $22.21M | 3.91% | +89.9K | +14.8% | Added | 1.05% |
| 8 | WAY Waystar Holding Corp. | Technology | 925.8K | $19.01M | 3.35% | -716.4K | -43.6% | Reduced | 0.48% |
| 9 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 480.4K | $17.90M | 3.15% | +480.4K | – | New | 0.5% |
| 10 | ORKA Oruka Therapeutics, Inc. | Healthcare | 177.1K | $16.86M | 2.97% | +44.6K | +33.7% | Added | 0.28% |
| 11 | CI Cigna Group | Healthcare | 57.8K | $15.92M | 2.8% | +57.8K | – | New | 0.02% |
| 12 | SNY Sanofi | Healthcare | 364.2K | $15.54M | 2.73% | +124.5K | +52.0% | Added | 0.03% |
| 13 | ICLR Icon Plc | Healthcare | 88.2K | $15.32M | 2.7% | -218.2K | -71.2% | Reduced | 0.11% |
| 14 | VTRS Viatris Inc | Healthcare | 954.3K | $15.15M | 2.67% | +954.3K | – | New | 0.08% |
| 15 | RAPP Rapport Therapeutics, Inc. | Healthcare | 307.7K | $12.82M | 2.26% | -59.2K | -16.1% | Reduced | 0.64% |
Tip. Select a row to see that position’s full history at Sio Capital Management.
As of its Q2 2026 13F filing, Sio Capital Management, LLC’s five largest positions were Anteris Technologies Global Corp. (AVR) at 9.6%, Cencora, Inc. (COR) at 8.6%, Maximus, Inc. (MMS) at 6.8%, Allogene Therapeutics, Inc. (ALLO) at 4.9%, Globus Medical Inc (GMED) at 4.2% of the reported portfolio.
Sio Capital Management, LLC reported a 13F portfolio worth $568.13M across 50 positions for Q2 2026. That is down 15.4% from the previous quarter.
Its largest purchases by value were Allogene Therapeutics, Inc. ($27.71M), Globus Medical Inc ($23.85M), Cencora, Inc. ($20.57M). It opened 13 new positions.
Its largest sales by value were Icon Plc ($37.90M), Dianthus Therapeutics, Inc. ($30.30M), Corcept Therapeutics Inc ($27.20M). It exited 27 positions entirely.
From the Form 13F-HR reports Sio Capital Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.